Progyny, Inc. is classed by the SEC under Services-Misc Health & Allied Services, NEC (industry code 8090), based in New York, NY. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $1.3 billion and a profit of $59 million (its filed statements).
Usage businessServices-Misc Health & Allied Services, NECNew York, NYfilings since 20129 of 9 filed
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a usage business: prior from its industry code (SEC 8090, Services-Misc Health & Allied Services, NEC); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 6.6 out of ten, 9 of 9 metrics filed: past 8.4 out of ten, present 6.3 out of ten, future 5.2 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 8.2 out of ten. No warning events in its filings since 2017. 82nd percentile among 11 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 8.4 out of ten. +30.2% a year over 6 filed years; profitable in 6 of 6. 84th percentile among 10 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 8.8 out of ten. Share count shrank 3.5% a year. 66% of cash flow returned. Insiders: 24 sales, 1 purchases. 88th percentile among 7 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Financial health (present): 7.5 out of ten. ROE 11%: 11¢ of profit per shareholder dollar. Leverage 30%: owes 30¢ per asset dollar. 75th percentile among 10 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 5.7 out of ten. top 43% of 10 in its family; net margin 4.5%. 57th percentile among 10 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 5.6 out of ten. top 44% of 7 in its family for leadership; chief executive since 2022. 56th percentile among 7 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
Room to expand (future): 5.0 out of ten. bottom 50% of 10 in its family for room to expand. 50th percentile among 10 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 6.2 out of ten. top 38% of 10 in its family for growth drivers. 62nd percentile among 10 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 4.2 out of ten. bottom 42% of 10 in its family for expectations against reality. 42nd percentile among 10 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-02-27 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-07 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-06 (on EDGAR). Newest filing: Form 4, 2026-09-28. Filings on record since 2012. Read from EDGAR 2026-10-12.
Where the revenue comes from
Product and service lines in fiscal 2025: Fertility Benefit Services 65%, Pharmacy Benefit Services 36%. As tagged in its annual report (Form 10-K, filed 2026-02-27).
Who runs it
Anevski, Peter (CHIEF EXECUTIVE OFFICER); Schlanger, David J (Executive Chairman); Sturmer, Michael E (PRESIDENT); Livingston, Mark S. (CHIEF FINANCIAL OFFICER); Cummings, Melissa B (Chief Operating Officer); Clapp, Geoffrey (Chief Product Officer); Swartz, Allison (EVP, GC); Gordon, Kevin K (director); Scott, Cheryl (director); Bierbower, Elizabeth D (director); and 5 more. 15 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.